Citius Oncology, Inc. (CTOR)
NASDAQ:CTOR
Want to see CTOR full AI Analyst Report?
CTOR Stock Chart & Stats
$1.07
-$0.06(-4.78%)
At close: 4:00 PM EST
$1.07
-$0.06(-4.78%)
Day’s Range― - ―
52-Week Range$0.49 - $6.19
Previous CloseN/A
Volume120.49K
Average Volume (3M)76.71K
Market Cap
$62.27M
Enterprise Value$62.55M
Total Cash (Recent Filing)$2.63M
Total Debt (Recent Filing)$3.80M
Price to Earnings (P/E)―
Beta1.27
Next Earnings
Aug 18, 2026EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.47
Shares Outstanding92,981,200
10 Day Avg. Volume79,851
30 Day Avg. Volume76,714
Financial Highlights & Ratios
PEG Ratio-0.45
Price to Book (P/B)3.32
Price to Sales (P/S)0.00
P/FCF Ratio-27.08
Enterprise Value/Market Cap1.00
Enterprise Value/Revenue11.15
Enterprise Value/Gross Profit13.92
Enterprise Value/Ebitda-1.52
Forecast
1Y Price Target
$4.00Price Target Upside273.83% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.16
Revenue Forecast (FY)$20.82M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Balance Sheet FlexibilityRelatively low leverage provides financial flexibility to fund near-term commercial roll‑out and clinical programs without immediate heavy interest burden. This reduces insolvency risk and preserves optionality for strategic financings or partnerships over the next 2–6 months.
Early Commercial Traction For LYMPHIRSequential orders, repeat purchases, broad formulary progress and substantial insurance coverage signal initial market adoption and distribution scale. That structural uptake supports a potential durable revenue stream as launch execution and access continue to expand.
Promising Clinical Data Supports Label ExpansionInvestigator‑initiated combo activity with durable responses and planned Phase 2 expansion creates a pathway to broaden indications beyond CTCL. Positive translational signals can materially increase addressable market and partnership interest over the medium term.
Bears Say
Pre-revenue With Widening Operating LossesAs a development-stage oncology company with no product revenue, continued widening losses erode equity and require external funding. Without durable revenue growth, the firm remains exposed to dilution and constrained reinvestment capacity for commercialization and R&D.
Growing Cash Burn And Negative Free Cash FlowMaterial and accelerating negative free cash flow increases the likelihood of near-term financing needs. That structural cash burn can force dilutive equity raises or onerous debt terms, limiting long-term strategic flexibility and complicating sustained commercial investment.
Nasdaq Listing Non-compliance / Delisting RiskA formal non-compliance notice creates a material structural risk to liquidity and investor confidence. Potential delisting would raise cost of capital, hinder secondary financings and impair partnerships and commercial distribution over the coming months absent corrective action.
Citius Oncology News
CTOR FAQ
What was Citius Oncology, Inc.’s price range in the past 12 months?
Citius Oncology, Inc. lowest stock price was $0.49 and its highest was $6.19 in the past 12 months.
What is Citius Oncology, Inc.’s market cap?
Citius Oncology, Inc.’s market cap is $62.27M.
When is Citius Oncology, Inc.’s upcoming earnings report date?
Citius Oncology, Inc.’s upcoming earnings report date is Aug 18, 2026 which is in 58 days.
How were Citius Oncology, Inc.’s earnings last quarter?
Citius Oncology, Inc. released its earnings results on May 15, 2026. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.01 by -$0.26.
Is Citius Oncology, Inc. overvalued?
According to Wall Street analysts Citius Oncology, Inc.’s price is currently Undervalued.
Does Citius Oncology, Inc. pay dividends?
Citius Oncology, Inc. does not currently pay dividends.
What is Citius Oncology, Inc.’s EPS estimate?
Citius Oncology, Inc.’s EPS estimate is -0.04.
How many shares outstanding does Citius Oncology, Inc. have?
Citius Oncology, Inc. has 92,981,200 shares outstanding.
What happened to Citius Oncology, Inc.’s price movement after its last earnings report?
Citius Oncology, Inc. reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.01. Following the earnings report the stock price went down -14.019%.
Which hedge fund is a major shareholder of Citius Oncology, Inc.?
Currently, no hedge funds are holding shares in CTOR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Citius Oncology Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$4.00 (273.83% Upside)
$4.00 (273.83% Upside)
Blogger Sentiment
Bullish
CTOR Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-56.83%
12-Months-Change
Fundamentals
Return on Equity
-99.47%
Trailing 12-Months
Asset Growth
10.13%
Trailing 12-Months
Company Description
Citius Oncology, Inc.
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
CTOR Stock 12 Month Forecast
Average Price Target
$4.00
▲(273.83% Upside)
Technical Analysis
Ownership Overview
6.58% Insiders
0.79% Mutual Funds
9.88% Other Institutional Investors
82.11% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---